Details
| Translated title of the contribution | Proliferative Forms Need to be Treated - Therapy of Lupus nephritis: Standards and Prospects for the Future |
|---|---|
| Original language | German |
| Pages (from-to) | 376-382 |
| Number of pages | 7 |
| Journal | Klinikarzt |
| Volume | 35 |
| Issue number | 9 |
| Publication status | Published - 29 Sept 2006 |
| Externally published | Yes |
Abstract
Lupus nephritis can be considered as an essential prognostic factor for the progression of systemic lupus erythematodes. There is no question that proliferative forms of lupus nephritis are to be treated with immunosuppressants. Since introduction of the standard therapy cyclophosphamide in the late eighties of the last century, alternative therapies were tried due to the various adverse effects of cyclophosphamide for example frequent secondary infections and ovarial insufficiency in young women. Based on clinical trials we can speak of therapeutic options nowadays that are probably as reliable as cyclophosphamide as induction therapy. Besides dose minimization concepts for cyclophosphamide including azathioprine as sequential therapy, induction therapies with azathioprine or mycophenolate mofetil (MMF) are discussed. The paper focuses the importance of these immunosuppressants against the background of other established substances as cyclosporine considering the actual clinical trial. Furthermore, it gives a survey of further therapeutic options of lupus nephritis as immunoadsorption or the anti-CD-20-antibody rituximab, most of them only suitable for additional application to current immunosuppression. Also future prospects are given.
ASJC Scopus subject areas
- Medicine(all)
- General Medicine
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Klinikarzt, Vol. 35, No. 9, 29.09.2006, p. 376-382.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Proliferative Formen bedürfen einer Behandlung - Therapie der Lupusnephritis
T2 - Standards und Zukunftsperspektiven
AU - Blume, Cornelia
AU - Grabensee, B.
PY - 2006/9/29
Y1 - 2006/9/29
N2 - Lupus nephritis can be considered as an essential prognostic factor for the progression of systemic lupus erythematodes. There is no question that proliferative forms of lupus nephritis are to be treated with immunosuppressants. Since introduction of the standard therapy cyclophosphamide in the late eighties of the last century, alternative therapies were tried due to the various adverse effects of cyclophosphamide for example frequent secondary infections and ovarial insufficiency in young women. Based on clinical trials we can speak of therapeutic options nowadays that are probably as reliable as cyclophosphamide as induction therapy. Besides dose minimization concepts for cyclophosphamide including azathioprine as sequential therapy, induction therapies with azathioprine or mycophenolate mofetil (MMF) are discussed. The paper focuses the importance of these immunosuppressants against the background of other established substances as cyclosporine considering the actual clinical trial. Furthermore, it gives a survey of further therapeutic options of lupus nephritis as immunoadsorption or the anti-CD-20-antibody rituximab, most of them only suitable for additional application to current immunosuppression. Also future prospects are given.
AB - Lupus nephritis can be considered as an essential prognostic factor for the progression of systemic lupus erythematodes. There is no question that proliferative forms of lupus nephritis are to be treated with immunosuppressants. Since introduction of the standard therapy cyclophosphamide in the late eighties of the last century, alternative therapies were tried due to the various adverse effects of cyclophosphamide for example frequent secondary infections and ovarial insufficiency in young women. Based on clinical trials we can speak of therapeutic options nowadays that are probably as reliable as cyclophosphamide as induction therapy. Besides dose minimization concepts for cyclophosphamide including azathioprine as sequential therapy, induction therapies with azathioprine or mycophenolate mofetil (MMF) are discussed. The paper focuses the importance of these immunosuppressants against the background of other established substances as cyclosporine considering the actual clinical trial. Furthermore, it gives a survey of further therapeutic options of lupus nephritis as immunoadsorption or the anti-CD-20-antibody rituximab, most of them only suitable for additional application to current immunosuppression. Also future prospects are given.
KW - Anti-lymphocyte antibodies
KW - Classification
KW - Gentherapy
KW - Immun-adsorption
KW - Immunsuppressants
KW - Lupus nephritis
KW - Plasmapheresis
UR - http://www.scopus.com/inward/record.url?scp=33750319373&partnerID=8YFLogxK
U2 - 10.1055/s-2006-954835
DO - 10.1055/s-2006-954835
M3 - Artikel
AN - SCOPUS:33750319373
VL - 35
SP - 376
EP - 382
JO - Klinikarzt
JF - Klinikarzt
SN - 0341-2350
IS - 9
ER -